Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction

por Sale, Matthew J., Balmanno, Kathryn, Cook, Simon J.
Publicado 2019

Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling

por Cook, Simon J., Stuart, Kate, Gilley, Rebecca, Sale, Matthew J.
Publicado 2017

ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1

por Balmanno, Kathryn, Kidger, Andrew M., Byrne, Dominic P., Sale, Matthew J., Nassman, Nejma, Eyers, Patrick A., Cook, Simon J.
Publicado 2023

Lysine Acetylation Controls Local Protein Conformation by Influencing Proline Isomerization

por Howe, Françoise S., Boubriak, Ivan, Sale, Matthew J., Nair, Anitha, Clynes, David, Grijzenhout, Anne, Murray, Struan C., Woloszczuk, Ronja, Mellor, Jane
Publicado 2014

The ribosomal S6 kinase 2 (RSK2)–SPRED2 complex regulates the phosphorylation of RSK substrates and MAPK signaling

por Lopez, Jocelyne, Bonsor, Daniel A., Sale, Matthew J., Urisman, Anatoly, Mehalko, Jennifer L., Cabanski-Dunning, Miranda, Castel, Pau, Simanshu, Dhirendra K., McCormick, Frank
Publicado 2023

RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome–associated cardiac hypertrophy

por Cuevas-Navarro, Antonio, Wagner, Morgan, Van, Richard, Swain, Monalisa, Mo, Stephanie, Columbus, John, Allison, Madeline R., Cheng, Alice, Messing, Simon, Turbyville, Thomas J., Simanshu, Dhirendra K., Sale, Matthew J., McCormick, Frank, Stephen, Andrew G., Castel, Pau
Publicado 2023

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models

por Winkler, Claudia, Armenia, Joshua, Jones, Gemma N., Tobalina, Luis, Sale, Matthew J., Petreus, Tudor, Baird, Tarrion, Serra, Violeta, Wang, Anderson T., Lau, Alan, Garnett, Mathew J., Jaaks, Patricia, Coker, Elizabeth A., Pierce, Andrew J., O’Connor, Mark J., Leo, Elisabetta
Publicado 2020

Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization

por Young, Lucy C., Goldstein de Salazar, Ruby, Han, Sae-Won, Huang, Zi Yi Stephanie, Merk, Alan, Drew, Matthew, Darling, Joseph, Wall, Vanessa, Grisshammer, Reinhard, Cheng, Alice, Allison, Madeline R., Sale, Matthew J., Nissley, Dwight V., Esposito, Dominic, Ognjenovic, Jana, McCormick, Frank
Publicado 2023

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

por Sale, Matthew J., Minihane, Emma, Monks, Noel R., Gilley, Rebecca, Richards, Frances M., Schifferli, Kevin P., Andersen, Courtney L., Davies, Emma J., Vicente, Mario Aladren, Ozono, Eiko, Markovets, Aleksandra, Dry, Jonathan R., Drew, Lisa, Flemington, Vikki, Proia, Theresa, Jodrell, Duncan I., Smith, Paul D., Cook, Simon J.
Publicado 2019

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF(V600E) amplification whereas KRAS(G13D) amplification promotes EMT-chemoresistance

por Sale, Matthew J., Balmanno, Kathryn, Saxena, Jayeta, Ozono, Eiko, Wojdyla, Katarzyna, McIntyre, Rebecca E., Gilley, Rebecca, Woroniuk, Anna, Howarth, Karen D., Hughes, Gareth, Dry, Jonathan R., Arends, Mark J., Caro, Pilar, Oxley, David, Ashton, Susan, Adams, David J., Saez-Rodriguez, Julio, Smith, Paul D., Cook, Simon J.
Publicado 2019